LKQ Q2 revenue misses expectations on European weakness
LKQ Q2 revenue misses expectations on European weakness
Overview
US auto parts supplier's Q2 revenue fell 3%, missing analyst expectations
Adjusted EPS for Q2 missed analyst expectations
Company repurchased 1.9 mln shares for $52 mln in Q2
Outlook
LKQ lowers 2026 organic revenue growth outlook to (3.0%) to (1.0%) from (0.5%) to 1.5%
Company cuts 2026 diluted EPS forecast to $1.78-$2.08 from $2.16-$2.46
LKQ says actions in Europe are focused on restoring service levels and aligning costs with demand
Result Drivers
NORTH AMERICA RECOVERY - North America returned to positive organic growth for the first time in nine quarters, driven by record alternative-parts utilization and improving repairable claims
EUROPEAN WEAKNESS - Europe fell short of expectations due to ERP implementation issues in Germany and lower volumes in the UK and Benelux, partially offset by cost reductions
SPECIALTY SEGMENT RESILIENCE - Specialty delivered growth despite a challenging end-market environment and continued macro-economic pressure on consumers
Company press release: ID:nGNX5ZMkJp
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Miss | $3.4 bln | $3.48 bln (7 Analysts) |
Q2 Adjusted EPS | Miss | $0.67 | $0.71 (9 Analysts) |
Q2 EPS |
| $0.52 |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the auto, truck & motorcycle parts peer group is "buy"
Wall Street's median 12-month price target for LKQ Corp is $41.00, about 55.4% above its July 29 closing price of $26.39
The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 10 three months ago
Reuters Recommended Reads
July 29 - Auto parts retailer O'Reilly lifts annual profit forecast on sustained replacement parts demand
July 29 - Monro Q1 sales fall 4.6%, but slightly beat estimates
July 29 - Teva Pharm seeking details on Trump drug tariffs plan, CEO says
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Recent news on LKQ
See all newsLKQ Corp reports results for the quarter ended September 30 - Earnings Summary
US STOCKS ON THE MOVE-Wesco, Mobileye, Glaukos
U.S. STOCKS ON THE MOVE-ADT, Equinix, Cognizant
LKQ rises as it halts strategic review, extends buyback program
LKQ halts strategic review; extends share buyback program (updated)